Seems like it's almost there...
Press Release[...]The US Food and Drug Administration (FDA) has granted fast track designation for Keyzilen™ (AM-101) in acute peripheral (inner ear) tinnitus following cochlear injury or otitis media in adults.
[...]The Fast Track program was created by the FDA to facilitate the development and expedite the review of new drugs that are intended to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. [...]
Member
FDA fast-tracking is almost exclusively used for terminal illness medications related to cancer/etc. It seems having a professional business model and funding behind tinnitus medications CAN help in the lobbying process. Amazing. Crossing my fingers!